Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 3.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 162,023 shares of the company’s stock after selling 6,589 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned approximately 0.07% of Hims & Hers Health worth $3,918,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. SlateStone Wealth LLC raised its stake in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after buying an additional 413 shares in the last quarter. Blume Capital Management Inc. raised its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after purchasing an additional 628 shares during the last quarter. Harbour Investments Inc. increased its stake in Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after purchasing an additional 833 shares during the last quarter. Finally, Stonekeep Investments LLC lifted its position in shares of Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after buying an additional 882 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

HIMS stock opened at $28.10 on Friday. The stock’s 50 day moving average price is $34.24 and its 200 day moving average price is $30.99. The firm has a market cap of $6.24 billion, a P/E ratio of 63.87 and a beta of 1.65. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of recent analyst reports. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Leerink Partners raised their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. Piper Sandler boosted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Truist Financial dropped their price target on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research note on Thursday, April 10th. Finally, BTIG Research started coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $38.08.

Insider Transactions at Hims & Hers Health

In other news, insider Irene Becklund sold 2,936 shares of the stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $26.49, for a total transaction of $77,774.64. Following the transaction, the insider now directly owns 5,071 shares in the company, valued at $134,330.79. This represents a 36.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $35.22, for a total transaction of $3,522,000.00. Following the completion of the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at $983,271.96. This represents a 78.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 712,998 shares of company stock worth $27,992,450 over the last ninety days. 17.71% of the stock is currently owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.